Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 69.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 25,380 shares of the company's stock after selling 56,617 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.05% of Axsome Therapeutics worth $2,147,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Assetmark Inc. purchased a new position in Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd purchased a new position in Axsome Therapeutics in the fourth quarter valued at about $64,000. Aquatic Capital Management LLC purchased a new position in Axsome Therapeutics in the fourth quarter valued at about $76,000. KBC Group NV boosted its holdings in Axsome Therapeutics by 40.5% in the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock valued at $113,000 after purchasing an additional 385 shares during the last quarter. Finally, Xponance Inc. boosted its holdings in Axsome Therapeutics by 11.6% in the fourth quarter. Xponance Inc. now owns 2,659 shares of the company's stock valued at $225,000 after purchasing an additional 277 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company's stock.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. This represents a 6.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.30% of the company's stock.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock traded down $1.10 on Friday, reaching $107.76. 435,267 shares of the company were exchanged, compared to its average volume of 682,708. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. The company's 50-day moving average is $112.01 and its two-hundred day moving average is $104.70. The firm has a market cap of $5.31 billion, a price-to-earnings ratio of -17.99 and a beta of 0.46. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. The business had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. As a group, research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AXSM has been the subject of a number of analyst reports. Wells Fargo & Company reissued an "overweight" rating and issued a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a report on Tuesday, May 6th. William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Bank of America upped their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Jefferies Financial Group assumed coverage on Axsome Therapeutics in a report on Monday, April 7th. They set a "buy" rating and a $200.00 target price on the stock. Finally, Truist Financial increased their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $172.14.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.